

ASX Announcement

CathRx announces commencement of pilot trial for its irrigated ablation catheter

Sydney 17 June 2009: Cardiac catheter manufacturer CathRx Ltd (ASX: CXD) today announced it had commenced a human pilot trial of its first therapeutic catheter for use in both atrial flutter and atrial fibrillation procedures. The irrigated ablation catheter was used in a procedure to treat atrial flutter in a human patient at the Monash Medical Centre in Victoria.

Speaking about the trial, Neil Anderson said, "The commencement of this first in man trial demonstrates CathRx's continued execution of our commercialization plan. We are excited by the achievement of our first procedure with a CathRx therapeutic device and we are looking forward to the completing the trial, collecting the data and eventually releasing our products to the market."

The data collected from the trial will be part of the Company's process to obtain CE Mark approval.

About the Trial

Name of Trial	<ul style="list-style-type: none"> CRX0004-M – Investigation of an irrigated ablation catheter
Primary end points	<ul style="list-style-type: none"> Pilot trial is not subject to end points
Secondary end points	<ul style="list-style-type: none"> Pilot trial is not subject to end points
Observations/Data collected	<ul style="list-style-type: none"> Data required on Case Report Forms. Data collected will include the following: <ul style="list-style-type: none"> Adverse events and Complications Achievement of bidirectional block Procedure time Fluoroscopy time
Blinding status	<ul style="list-style-type: none"> None
No of subjects to complete trial	<ul style="list-style-type: none"> Total 15
No of Subjects to be used for regulatory submission	<ul style="list-style-type: none"> Total 15
Subject Selection Criteria	<ul style="list-style-type: none"> Patients that have been scheduled for first atrial flutter ablation procedure Over the age of 18 years Are not pregnant Are English-speaking Are not of Aboriginal or Torres Strait Islander descent Are not involved in concealment or deception Are not in emergency/intensive care, neonatal nor have impaired capacity
Trial Location	<ul style="list-style-type: none"> Australia
Commercial Partners Involved	<ul style="list-style-type: none"> CathRx only
Expected Completion of Trial	<ul style="list-style-type: none"> Third quarter Calendar year 2009
Expected completion of regulatory submission	<ul style="list-style-type: none"> Third quarter of calendar year 2009

About CathRx

CathRx is a medical device company which manufactures and markets advanced cardiac catheter solutions for the treatment of people suffering from electrical problems of the heart known as cardiac arrhythmias. CathRx's proprietary diagnostic and therapeutic catheters are designed to give physicians the tools to successfully treat patients with speed, safety and precision. CathRx's first diagnostic products are now being sold in Europe.



CathRx Ltd
ABN 23 089 310 421

5 Parkview Drive
Homebush Bay NSW 2127
Australia
Telephone +61 (0)2 9397 5700
Facsimile +61 (0)2 9397 5701
www.cathrx.com

About cardiac arrhythmias

Cardiac arrhythmia describes a group of increasingly common conditions where there is abnormal electrical activity in the heart. The beating of a normal heart is controlled by electrical impulses. When these impulses are uncoordinated the heart fails to function properly. This can result in complications ranging from fatigue to stroke and even death. More than 10 million people worldwide suffer from abnormal heart rhythms. Atrial fibrillation is the most common form of arrhythmia and affects over 5 million people worldwide. Current drug therapies often fail to control the problem and can have side effects. Physicians worldwide are increasingly using cardiac catheters to diagnose and successfully treat arrhythmias.

Forward Looking Statements

To the extent that this release may contain projections or forward looking statements, they are based upon current expectations and are subject to uncertainty and contingencies, many of which are outside the control of the company. Actual performance, events, results or outcomes may differ for a variety of reasons. Furthermore, the assumptions underlying the forward looking statements could prove inaccurate or incorrect. Therefore, there can be no assurance that the results contemplated in the forward looking statements will be realised.

